Latest Biotech News

Johnson & Johnson received FDA approval expanding the label for Caplyta (originating from Intra‑Cellular Therapies) into adjunctive treatment for major depressive disorder, a regulatory win tied...

Eli Lilly reported Phase II data showing its amylin receptor agonist eloralintide achieved dose‑dependent weight losses up to ~20% at Week 48 with an apparently favorable GI tolerability profile,...

Mark Zuckerberg and Priscilla Chan’s Biohub unveiled a large‑scale initiative to merge frontier AI with experimental biology and announced the integration of EvolutionaryScale’s team — the...

A patient in Intellia Therapeutics’ in vivo CRISPR trial for transthyretin (ATTR) amyloidosis died after hospitalization for liver injury, prompting intensified safety reviews and an FDA...

The Chan Zuckerberg Biohub announced a major expansion that folds EvolutionaryScale’s AI-for-biology team into a new, large-scale initiative pairing frontier compute with experimental biology. The...

Researchers published an atomically accurate, de novo antibody design method using RFdiffusion that produced antibodies with confirmed atomic binding poses by cryo‑electron microscopy. The Nature...

Scientists demonstrated that human gastric organoids engineered with pancreatic reprogramming factors can produce insulin-secreting cells after transplantation into mice, lowering blood glucose...

Evommune, an inflammation-focused biotech, priced a $150 million initial public offering as investors showed appetite for select clinical-stage immunology names despite a constrained IPO...

Hepta Bio, founded by ex‑Illumina and Grail scientists, raised $6.7 million to commercialize a transformer-based AI that decodes cell-free DNA methylation patterns to detect metabolic liver...

BIOVECTRA and Revolution Biomanufacturing announced an integrated service combining AI-driven mRNA sequence optimization with end-to-end GMP manufacturing for plasmid DNA, mRNA, LNPs and sterile...

Ginkgo Bioworks secured a BARDA contract — up to $22.2 million — through the BioMaP Consortium to develop cost‑reducing, rapid biomanufacturing approaches for monoclonal antibodies against...

The FDA released a second tranche of Commissioner’s National Priority Vouchers, adding six drugs — including high-profile obesity candidates from Eli Lilly and Novo Nordisk — to a program that...

Abzena and Mabqi announced a strategic partnership to integrate Mabqi’s LiteMab antibody discovery platform with Abzena’s cell line, process development and GMP manufacturing services. The...

The Federal Trade Commission flagged procedural and antitrust concerns over Novo Nordisk’s bid for obesity developer Metsera, noting the deal’s structure could transfer “significant rights,...

The FDA released a second batch of its National Priority (commissioner) vouchers, speeding review pathways for selected drug candidates, and the administration simultaneously announced deals with...

The FDA issued a complete response letter for Biohaven’s troriluzole New Drug Application in spinocerebellar ataxia, rejecting the package that relied heavily on real‑world evidence and external...

Braveheart Bio closed a $185 million financing to advance a small‑molecule candidate for obstructive hypertrophic cardiomyopathy toward registration‑enabling studies, positioning it as a potential...

Researchers demonstrated atomically precise, de novo antibody design using RFdiffusion and validated binding poses with cryo‑EM, marking a step change in computational biologics design published...

China’s Ministry of Commerce said it will lift export restrictions on Illumina sequencers effective November 10, reopening a major market after months of trade curbs. Illumina confirmed the...

The FDA approved UCB’s KYGEVVI (doxecitine and doxribtimine) as the first treatment for thymidine kinase 2 deficiency (TK2d), an ultra‑rare mitochondrial disorder with high pediatric mortality....